Ting B Zhang

US Patent:

20220248250, Aug 4, 2022

Filed:

Apr 18, 2022

Appl. No.:

17/723180

Inventors:

- Bellevue WA, US
Ting Zhang - Bellevue WA, US
Vikas Ranjan - Bellevue WA, US

International Classification:

H04W 24/10
H04L 41/5009
G06N 20/00
H04B 17/318
H04W 4/24

Abstract:

Presented here is a method to predict whether a user of a wireless telecommunication network will report a problem or issue associated with the wireless telecommunication network. A processor can obtain multiple key performance indicators (KPIs) describing a user experience with the wireless telecommunication network. The processor can calculate at least a daily value of each KPI according to a rule specific to the KPI. The processor can create an image representing a value of each KPI, where a first axis of the image identifies the KPI, and where a second axis of the image represents the daily value of the KPI. The processor can predict whether the user of the wireless telecommunication network will report the problem by providing the image to a machine learning model and receiving a prediction from the machine learning model whether the user of the wireless telecommunication network will report the problem.

US Patent:

20190104427, Apr 4, 2019

Filed:

Sep 28, 2018

Appl. No.:

16/147309

Inventors:

- Bellevue WA, US
Doris Ho - Bellevue WA, US
Ting Zhang - Bellevue WA, US

International Classification:

H04W 24/08
H04M 3/51
H04M 3/22

Abstract:

Systems and methods are described herein for analyzing the performance of a communications network (e.g., a mobile telecommunications network) using customer-centric and/or subscriber-centric data and information. In some embodiments, the systems and method may determine key performance indicators for a communications network by accessing call detail records from multiple communications network sources, generating a database of one or more customer stats table (CSTs) based on the accessed call records, wherein the CSTs include records for each individual customers of the communications network, and determining one or more key performance indicators (KPIs) for the overall network based on the records stored by the one or more customer stats tables.

US Patent:

20180270346, Sep 20, 2018

Filed:

Mar 17, 2017

Appl. No.:

15/462735

Inventors:

- Bellevue WA, US
Le Roy Munar - Snoqualmie WA, US
Ting Zhang - Bellevue WA, US
Baquer Ali Chabuk Savar - Bellevue WA, US
Muhammad Tawhidur Rahman - Bellevue WA, US

International Classification:

H04M 3/22
H04M 15/00
H04L 29/06

Abstract:

Systems and methods are described herein for determining dropped call rates (DCR) for various communications networks, such as IP Multimedia Networks (IMS), which include Voice over LTE (VoLTE) networks. For example, the systems and methods utilize data (e.g. abnormal cause codes) generated by layers of the IMS networks, such as a Session Initiation Protocol (SIP) layer of the IMS network, when determining dropped call rates for IMS networks.

US Patent:

20180270678, Sep 20, 2018

Filed:

Mar 17, 2017

Appl. No.:

15/462746

Inventors:

- Bellevue WA, US
Doris Ho - Bellevue WA, US
Ting Zhang - Bellevue WA, US

International Classification:

H04W 24/08
H04M 3/22

Abstract:

Systems and methods are described herein for analyzing the performance of a communications network (e.g., a mobile telecommunications network) using customer-centric and/or subscriber-centric data and information. In some embodiments, the systems and method may determine key performance indicators for a communications network by accessing call detail records from multiple communications network sources, generating a database of one or more customer stats table (CSTs) based on the accessed call records, wherein the CSTs include records for each individual customers of the communications network, and determining one or more key performance indicators (KPIs) for the overall network based on the records stored by the one or more customer stats tables.

US Patent:

20180030036, Feb 1, 2018

Filed:

Dec 7, 2015

Appl. No.:

15/534029

Inventors:

Ting ZHANG - Rahway NJ, US
Yi-Heng CHEN - Rahway NJ, US
Liangqin GUO - Rahway NJ, US
Alan HARUZA - Rahway NJ, US
Tianying JIAN - Rahway NJ, US
Bing LI - Rahway NJ, US
Dongfang MENG - Rahway NJ, US
Edward C. SHERER - Rahway NJ, US
Harold B. WOOD - Rahway NJ, US
Isao SAKURADA - Tokyo, JP
- Rahway NJ, US
- Tokyo, JP

Assignee:

MERCK SHARP & DOHME CORP. - Rahway NJ
MOCHIDA PHARMACEUTICAL CO., LTD - Tokyo

International Classification:

C07D 403/12
C07D 401/14
C07D 401/12
C07D 471/04

Abstract:

The present invention provides a compound of Formula I, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

US Patent:

20180022747, Jan 25, 2018

Filed:

Feb 12, 2016

Appl. No.:

15/550862

Inventors:

Dongfang MENG - Rahway NJ, US
Hong LI - Rahway NJ, US
Meng YANG - Rahway NJ, US
Manuel de Lera RUIZ - West Point PA, US
Sunita V. DEWNANI - Secaucus NJ, US
Tianying JIAN - Rahway NJ, US
Ting ZHANG - Rahway NJ, US
Louis-Charles CAMPEAU - Rahway NJ, US
Bart HARPER - Rahway NJ, US
Harold B. WOOD - Rahway NJ, US
Jiayi XU - Rahway NJ, US
Richard BERGER - West Point PA, US
Jane Yang WU - Rahway NJ, US
Robert K. ORR - Rahway NJ, US
Shawn P. WALSH - Kenilworth NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 471/04
C07D 403/12
C07D 498/04
C07D 417/14
C07D 513/04
C07D 471/14
C07D 413/14

Abstract:

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors.

US Patent:

20170129880, May 11, 2017

Filed:

Apr 10, 2015

Appl. No.:

15/303310

Inventors:

Isao Sakurada - Tokyo, JP
Tomokazu Hirabayashi - Tokyo, JP
Yoshitaka Maeda - Tokyo, JP
Hiroshi Nagasue - Tokyo, JP
Takashi Mizuno - Tokyo, JP
Jiayi Xu - Marlboro NJ, US
Ting Zhang - Princeton Junction NJ, US
Cameron Smith - Montgomery Village MD, US
Dann Parker - Cranford NJ, US

International Classification:

C07D 413/14
A61K 45/06
C07D 417/14
A61K 31/428
C07D 471/04
A61K 31/52
A61K 31/506
A61K 31/4439
C07D 519/00
A61K 31/497
A61K 31/501
A61K 31/423
A61K 31/437

Abstract:

In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

US Patent:

20170027916, Feb 2, 2017

Filed:

Apr 10, 2015

Appl. No.:

15/303322

Inventors:

- Rahway NJ, US
- Tokyo, JP
Yoshitaka Maeda - Gotemba City, JP
Hiroshi Nagasue - Gotemba City, JP
Takashi Mizuno - Gotemba City, JP
Jiayi Xu - Marlboro NJ, US
Ting Zhang - Princeton Junction NJ, US
Cameron Smith - Montgomery Village MD, US
Dann Parker - Cranford NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Mochida Pharmaceutical Co., Ltd. - Tokyo

International Classification:

A61K 31/439
A61K 45/06
A61K 31/444
A61K 31/506
A61K 31/501
C07D 519/00
C07D 413/14
C07D 498/04

Abstract:

In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.